Efficiency Study of Siwu Tang to Treat Brain Hypoperfusion Syndrome
Parole chiave
Astratto
Descrizione
We designed a randomized, double-blinded controlled study, and a total of 80 patients with brain hypoperfusion syndrome should be finished assessment in two years. The 80 patients with hypoperfusion syndrome were divided into as follows:1) control group, receiving siwu tang placebo 3 g bid continuously two weeks except ordinary treatment; 2) treatment group, receiving siwu tang 3 g bid continuously two weeks except ordinary treatment. The patients were assessed before, and 4 weeks (weeks±3 days) and 12 weeks (12 weeks±3 days) after siwu tang treatment, respectively. Primary outcome measure was cerebral blood flow by using single photon emission computed tomography (SPECT); Second outcome measure included severity of dizziness by using visual analogue scale (VAS); cognitive function by using Mini-Mental Status (MMSE), Cognitive Abilities Screening Instrument (CASI), and Clinical Dementia Rating (CDR); quality of life by using barthel index (BI) and Functional Independent Measure (FIM).
We predict that siwu tang can improve cerebral blood flow, and clinical manifestation including dizziness, and cognition function and quality of life in patients with brain hypoperfusion syndrome .
Date
| Ultimo verificato: | 09/30/2010 |
| Primo inviato: | 10/09/2010 |
| Iscrizione stimata inviata: | 10/13/2010 |
| Primo pubblicato: | 10/14/2010 |
| Ultimo aggiornamento inviato: | 10/13/2010 |
| Ultimo aggiornamento pubblicato: | 10/14/2010 |
| Data di inizio effettiva dello studio: | 06/30/2010 |
| Data di completamento primaria stimata: | 06/30/2012 |
| Data stimata di completamento dello studio: | 10/31/2012 |
Condizione o malattia
Intervento / trattamento
Drug: Siwu Tang
Fase
Criteri di idoneità
| Età idonea per lo studio | 18 Years Per 18 Years |
| Sessi idonei allo studio | All |
| Accetta volontari sani | sì |
| Criteri | Inclusion Criteria: - age between 18y/o to 80 y/o and had brain hypoperfusion syndrome such as dizziness - barthel index (BI) > 60。 - single photon emission computer tomography(SPECT) or MRI exam show hypoperfusion area Exclusion Criteria: - Patient had cancer or uremia,liver cirrhosis |
Risultato
Misure di esito primarie
1. cerebral blood flow [12 weeks after treatment]
Misure di esito secondarie
1. severity of dizziness [12 weeks after treatment]
2. cognitive function [12 weeks after treatment]
3. quality of life [12 weeks after treatment]
